Malignant Neoplasm — Trials

Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20,116
Recruiting: 10,894
Ph III recruiting: 1,280
Growth YoY: +12%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11,163)

clinicaltrialsPublishedShowing 351–400 of 4,300 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06408168	Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)	terminated	Phase 2	6	M.D. Anderson Cancer CenterOTHER	1	Jan 5, 2026	clinicaltrials
NCT06162351	A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer(TOPOLOGY)	terminated	Phase 2	14	Institut Curie